GNI Group Ltd
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical tri… Read more
GNI Group Ltd (3G6) - Net Assets
Latest net assets as of June 2025: €38.31 Billion EUR
Based on the latest financial reports, GNI Group Ltd (3G6) has net assets worth €38.31 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€67.72 Billion) and total liabilities (€29.41 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €38.31 Billion |
| % of Total Assets | 56.57% |
| Annual Growth Rate | 23.28% |
| 5-Year Change | 211.02% |
| 10-Year Change | 674.6% |
| Growth Volatility | 59.5 |
GNI Group Ltd - Net Assets Trend (2013–2024)
This chart illustrates how GNI Group Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GNI Group Ltd (2013–2024)
The table below shows the annual net assets of GNI Group Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €39.71 Billion | +10.15% |
| 2023-12-31 | €36.05 Billion | +81.98% |
| 2022-12-31 | €19.81 Billion | +2.83% |
| 2021-12-31 | €19.27 Billion | +50.88% |
| 2020-12-31 | €12.77 Billion | -2.49% |
| 2019-12-31 | €13.10 Billion | -4.54% |
| 2018-12-31 | €13.72 Billion | +1.76% |
| 2017-12-31 | €13.48 Billion | +197.41% |
| 2016-12-31 | €4.53 Billion | -11.58% |
| 2015-12-31 | €5.13 Billion | -11.36% |
| 2014-12-31 | €5.78 Billion | +45.62% |
| 2013-12-31 | €3.97 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GNI Group Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1682179700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €9.89 Billion | 27.13% |
| Other Components | €26.56 Billion | 72.87% |
| Total Equity | €36.45 Billion | 100.00% |
GNI Group Ltd Competitors by Market Cap
The table below lists competitors of GNI Group Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Parksystems Corp
KQ:140860
|
$772.61 Million |
|
Korian S.A.
LSE:0OPS
|
$772.84 Million |
|
Ennoconn Corp
TW:6414
|
$772.89 Million |
|
Cleanaway Co Ltd
TW:8422
|
$773.23 Million |
|
Firstsource Solutions Limited
NSE:FSL
|
$772.57 Million |
|
Wuxi Huadong Heavy Machinery Co Ltd
SHE:002685
|
$772.37 Million |
|
Capitol Federal Financial Inc
NASDAQ:CFFN
|
$771.67 Million |
|
TRTPF
PINK:TRTPF
|
$771.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GNI Group Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 33,794,414,000 to 36,446,115,000, a change of 2,651,701,000 (7.8%).
- Net income of 1,098,233,000 contributed positively to equity growth.
- Share repurchases of 69,000 reduced equity.
- New share issuances of 326,000 increased equity.
- Other factors increased equity by 1,553,211,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.10 Billion | +3.01% |
| Share Repurchases | €69.00K | -0.0% |
| Share Issuances | €326.00K | +0.0% |
| Other Changes | €1.55 Billion | +4.26% |
| Total Change | €- | 7.85% |
Book Value vs Market Value Analysis
This analysis compares GNI Group Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €289.91 | €17.30 | x |
| 2018-12-31 | €289.00 | €17.30 | x |
| 2019-12-31 | €246.54 | €17.30 | x |
| 2020-12-31 | €252.80 | €17.30 | x |
| 2021-12-31 | €397.38 | €17.30 | x |
| 2022-12-31 | €441.59 | €17.30 | x |
| 2023-12-31 | €678.01 | €17.30 | x |
| 2024-12-31 | €726.67 | €17.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GNI Group Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.65%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.97x
- Recent ROE (3.01%) is above the historical average (-1.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -25.78% | -398.91% | 0.04x | 1.68x | €-1.01 Billion |
| 2014 | -7.39% | -68.99% | 0.07x | 1.53x | €-769.40 Million |
| 2015 | -16.25% | -61.32% | 0.16x | 1.66x | €-1.01 Billion |
| 2016 | -15.73% | -39.26% | 0.22x | 1.78x | €-839.21 Million |
| 2017 | -1.50% | -6.62% | 0.17x | 1.36x | €-1.35 Billion |
| 2018 | -1.67% | -3.99% | 0.29x | 1.44x | €-1.40 Billion |
| 2019 | 1.70% | 2.44% | 0.36x | 1.93x | €-887.37 Million |
| 2020 | 11.44% | 12.87% | 0.42x | 2.11x | €158.12 Million |
| 2021 | 5.65% | 8.40% | 0.42x | 1.61x | €-819.85 Million |
| 2022 | 1.85% | 2.23% | 0.51x | 1.62x | €-1.71 Billion |
| 2023 | 23.95% | 31.12% | 0.42x | 1.85x | €4.71 Billion |
| 2024 | 3.01% | 4.65% | 0.33x | 1.97x | €-2.55 Billion |
Industry Comparison
This section compares GNI Group Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $-89,832,246
- Average return on equity (ROE) among peers: -27.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GNI Group Ltd (3G6) | €38.31 Billion | -25.78% | 0.77x | $772.60 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |